Integra LifeSciences Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Integra LifeSciences Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 113.7% bzw. 5.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 110.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.2% betragen.
Wichtige Informationen
113.7%
Wachstumsrate der Gewinne
110.5%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 5.8% |
| Zukünftige Eigenkapitalrendite | 17.2% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 13 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
Sep 08Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,789 | 99 | 189 | 205 | 10 |
| 12/31/2025 | 1,711 | 71 | 145 | 174 | 12 |
| 12/31/2024 | 1,613 | 1 | 38 | 84 | 12 |
| 9/30/2024 | 1,565 | -7 | 38 | 137 | N/A |
| 6/30/2024 | 1,567 | 24 | 59 | 142 | N/A |
| 3/31/2024 | 1,530 | 40 | 61 | 130 | N/A |
| 12/31/2023 | 1,542 | 68 | 73 | 140 | N/A |
| 9/30/2023 | 1,543 | 101 | 110 | 167 | N/A |
| 6/30/2023 | 1,545 | 131 | 155 | 208 | N/A |
| 3/31/2023 | 1,562 | 172 | 200 | 246 | N/A |
| 12/31/2022 | 1,558 | 181 | 217 | 264 | N/A |
| 9/30/2022 | 1,565 | 173 | 188 | 248 | N/A |
| 6/30/2022 | 1,567 | 166 | 205 | 263 | N/A |
| 3/31/2022 | 1,559 | 157 | 232 | 288 | N/A |
| 12/31/2021 | 1,542 | 169 | 264 | 312 | N/A |
| 9/30/2021 | 1,526 | 216 | 274 | 323 | N/A |
| 6/30/2021 | 1,509 | 206 | 262 | 310 | N/A |
| 3/31/2021 | 1,378 | 170 | 203 | 252 | N/A |
| 12/31/2020 | 1,372 | 134 | 140 | 204 | N/A |
| 9/30/2020 | 1,378 | 56 | 155 | 213 | N/A |
| 6/30/2020 | 1,387 | -3 | 78 | 207 | N/A |
| 3/31/2020 | 1,512 | 27 | 83 | 223 | N/A |
| 12/31/2019 | 1,518 | 50 | 97 | 231 | N/A |
| 9/30/2019 | 1,506 | 60 | 47 | 185 | N/A |
| 6/30/2019 | 1,493 | 101 | 124 | 200 | N/A |
| 3/31/2019 | 1,475 | 83 | 109 | 188 | N/A |
| 12/31/2018 | 1,472 | 61 | 122 | 200 | N/A |
| 9/30/2018 | 1,458 | 80 | 103 | 169 | N/A |
| 6/30/2018 | 1,371 | 70 | N/A | 135 | N/A |
| 3/31/2018 | 1,287 | 69 | N/A | 127 | N/A |
| 12/31/2017 | 1,188 | 65 | N/A | 115 | N/A |
| 9/30/2017 | 1,075 | 49 | N/A | 110 | N/A |
| 6/30/2017 | 1,047 | 66 | N/A | 111 | N/A |
| 3/31/2017 | 1,014 | 68 | N/A | 120 | N/A |
| 12/31/2016 | 992 | 75 | N/A | 116 | N/A |
| 9/30/2016 | 985 | 61 | N/A | 136 | N/A |
| 6/30/2016 | 958 | 9 | N/A | 108 | N/A |
| 3/31/2016 | 919 | 9 | N/A | 98 | N/A |
| 12/31/2015 | 883 | 7 | N/A | 105 | N/A |
| 9/30/2015 | 854 | 12 | N/A | 100 | N/A |
| 6/30/2015 | 827 | 53 | N/A | 111 | N/A |
| 3/31/2015 | 782 | 46 | N/A | 100 | N/A |
| 12/31/2014 | 797 | 36 | N/A | 84 | N/A |
| 9/30/2014 | 798 | 30 | N/A | 70 | N/A |
| 6/30/2014 | 814 | -10 | N/A | 70 | N/A |
| 3/31/2014 | 855 | -13 | N/A | 57 | N/A |
| 12/31/2013 | 697 | 22 | N/A | 53 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IART wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).
Ertrag vs. Markt: IART wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: IART wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: IARTDie Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: IARTDie Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IARTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.2%).